TNF receptor superfamily member 11b
Dernière mise à jour 20 nov. 2025
Respecte les directives éditoriales
- TéléchargerTélécharger
- Partager
- Language
- Discussion
- Ask Patient
- Version audio
- Ajouter aux sources préférées sur Google
The TNFRSF11B gene provides instructions for making a protein that plays an important role in bone remodeling, a normal process in which old bone is broken down and replaced by new bone. The TNFRSF11B protein is involved in the regulation of specialized cells called osteoclasts, which break down bone tissue during bone remodeling.
Sélections vidéo pour GènesBibliothèque vidéo
Normal function
The TNFRSF11B gene provides instructions for making a protein that plays an important role in bone remodeling, a normal process in which old bone is broken down and replaced by new bone. The TNFRSF11B protein is involved in the regulation of specialized cells called osteoclasts, which break down bone tissue during bone remodeling.
The TNFRSF11B protein belongs to a larger family of receptor proteins. Other proteins, called ligands, can fit into specific sites on receptor proteins like a key into a lock. Together, ligands and their receptors trigger signaling pathways that affect cell development and function. The TNFRSF11B protein works outside of the cell membrane.
The TNFRSF11B protein and a receptor protein called RANK can each attach to a ligand called RANKL. Because RANKL can only bind to one of these proteins at a time, the TNFRSF11B protein and RANK compete with one another. When RANKL is bound to RANK, a series of chemical signals cause osteoclasts to mature and turn on. This leads to the breakdown of bone. When RANKL is bound to the TNFRSF11B protein, these chemical signals are blocked. The TNFRSF11B protein is called a "decoy" receptor protein because no chemical signals are transmitted when RANKL is attached to this protein.
By influencing the amount of RANKL that is available to bind to RANK and activate osteoclasts, the TNFRSF11B protein plays a critical role in regulating the process of bone remodeling.
Conditions referring to this gene or chromosome
Other names
OCIF
OPG
osteoclastogenesis inhibitory factor
TR1
tumour necrosis factor receptor superfamily, member 11b
Related patient information and medicines

Patient information leaflet
Immunosuppression
Mycophenolate... Monoclonal antibodies - of which there are many ending in "mab", such as bevacizumab, rituximab and trastuzumab. Anti-TNF drugs such as etanercept Etanercept , infliximab, adalimumab, certolizumab and golimumab. (TNF stands for anti tumour necrosis factor, and some of the "mab" medicines above act against TNF, so there is some.

Patient information leaflet
Médicaments biologiques pour la polyarthrite rhumatoïde
They are made by living o... For example, some of these biological medicines block a chemical called tumour necrosis factor alpha (TNF-alpha) which plays an important role in causing inflammation in the joints. Medicines that block TNF incluent adalimumab, certolizumab pegol, etanercept, golimumab, and infliximab. The other biological medicines.

Patient information leaflet
Hidradénite suppurée
Hidradénite suppurée is a long-term (chronic) peau condition that leads to painful and repeated lumps of pus (boils or abscesses). Hidradenitis suppurativa tends to run in families; about one-third of people with hidradenitis suppurative have a family member who is affected. The most promising of these treatments are monoclonal antibodies,.

Patient information leaflet
Spondyloarthrite axiale
Biological medicines Biologics can be used to control the disease process. The main ones used for axial spondyloarthritis are called tumour necrosis factor (TNF) inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab or infliximab). Other medicines, such as secukinumab, bimekizumab or ixekizumab, may be used if TNF inhibitors have been.

Patient information leaflet
Spondylarthrite ankylosante
In ankylosing spondylitis, a chemical called cytokine tumour necrosis factor alpha (TNF-alpha) is involved in causing inflammation. Certain medicines in a group called TNF-alpha inhibitors... TNF-alpha inhibitors are also sometimes called anti-TNF-alpha drugs. In the UK the National Institute for Health and Care Excellence (NICE) recommends that.

Patient information leaflet
Syndrome de Marfan
The following lists the most common problems and symptoms that may develop. Treatments are available for most of these problems. It can also cause head... What causes Marfan syndrome. Marfan syndrome is caused by a change (mutation) in le génétiques material on one of votre chromosomes (chromosome number 15). The gene that is affected is responsible.
Lectures complémentaires et références
- TNF receptor superfamily member 11b; MedlinePlus, National Library of Medicine.
- Chong B, Hegde M, Fawkner M, Simonet S, Cassinelli H, Coker M, Kanis J, Seidel J, Tau C, Tuysuz B, Yuksel B, Love D; International Hyperphosphatasia Collaborative Group. Idiopathic hyperphosphatasia and TNFRSF11B mutations: relationships between phenotype and genotype. J Bone Miner Res. 2003 Dec;18(12):2095-104. doi: 10.1359/jbmr.2003.18.12.2095.
- Cundy T, Hegde M, Naot D, Chong B, King A, Wallace R, Mulley J, Love DR, Seidel J, Fawkner M, Banovic T, Callon KE, Grey AB, Reid IR, Middleton-Hardie CA, Cornish J. A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. Hum Mol Genet. 2002 Sep 1;11(18):2119-27. doi: 10.1093/hmg/11.18.2119.
- Janssens K, de Vernejoul MC, de Freitas F, Vanhoenacker F, Van Hul W. An intermediate form of juvenile Paget's disease caused by a truncating TNFRSF11B mutation. Bone. 2005 Mar;36(3):542-8. doi: 10.1016/j.bone.2004.12.004.
- Naot D, Choi A, Musson DS, Simsek Kiper PO, Utine GE, Boduroglu K, Peacock M, DiMeglio LA, Cundy T. Novel homozygous mutations in the osteoprotegerin gene TNFRSF11B in two unrelated patients with juvenile Paget's disease. Bone. 2014 Nov;68:6-10. doi: 10.1016/j.bone.2014.07.034. Epub 2014 Aug 6.
- Ralston SH, Taylor JP. Rare Inherited forms of Paget's Disease and Related Syndromes. Calcif Tissue Int. 2019 May;104(5):501-516. doi: 10.1007/s00223-019-00520-5. Epub 2019 Feb 13.
- Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997 Apr 18;89(2):309-19. doi: 10.1016/s0092-8674(00)80209-3.
- Whyte MP, Obrecht SE, Finnegan PM, Jones JL, Podgornik MN, McAlister WH, Mumm S. Osteoprotegerin deficiency and juvenile Paget's disease. N Engl J Med. 2002 Jul 18;347(3):175-84. doi: 10.1056/NEJMoa013096.
- Wuyts W, Van Wesenbeeck L, Morales-Piga A, Ralston S, Hocking L, Vanhoenacker F, Westhovens R, Verbruggen L, Anderson D, Hughes A, Van Hul W. Evaluation of the role of RANK and OPG genes in Paget's disease of bone. Bone. 2001 Jan;28(1):104-7. doi: 10.1016/s8756-3282(00)00411-7.
Partagez vos pensées ou expériences avec les autres dans notre communautés de patients.
Inscrivez-vous à la newsletter Patient
Votre dose hebdomadaire de conseils de santé clairs et fiables - rédigés pour vous aider à vous sentir informé, confiant et maître de la situation.
En vous abonnant, vous acceptez notre Politique de confidentialité. Vous pouvez vous désabonner à tout moment. Nous ne vendons jamais vos données.

